---
category: news
title: "Transgene and NEC Start Two Clinical Trials with TG4050, an AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers"
excerpt: "\"As each patient's cancer is unique, we have developed a therapy that turns their solid tumor's genetic signature into a ... Our partnership with NEC ensures that TG4050 is benefitting from its world-leading expertise in artificial intelligence and its unique algorithm that is used to select up to 30 patient-specific antigens that allow this ..."
publishedDateTime: 2020-01-06T23:00:00Z
sourceUrl: https://www.benzinga.com/pressreleases/20/01/b15081336/transgene-and-nec-start-two-clinical-trials-with-tg4050-an-ai-powered-cancer-vaccine-for-ovarian-a
ampUrl: https://amp.benzinga.com/amp/content/15081336
cdnAmpUrl: https://amp-benzinga-com.cdn.ampproject.org/c/s/amp.benzinga.com/amp/content/15081336
type: article
quality: 14
heat: -1
published: false

provider:
  name: Benzinga.com
  domain: benzinga.com

topics:
  - AI
  - AI in Healthcare

related:
  - title: "Transgene starts trials of ‘digital’ cancer vaccine with NEC"
    excerpt: "The French biotech is partnering with artificial intelligence (AI) specialist NEC on the new programme – called TG4050 ... who have a high risk of relapse after surgery and patients with ovarian cancer after surgery and adjuvant therapy. It was also given a green light for a trial in head and neck cancer by the UK Medicines and Healthcare ..."
    publishedDateTime: 2020-01-07T13:20:00Z
    sourceUrl: https://pharmaphorum.com/news/transgene-starts-trials-of-digital-cancer-vaccine-with-nec/
    type: article
    provider:
      name: pharmaphorum.com
      domain: pharmaphorum.com
    quality: 24
    images:
      - url: https://www.bing.com/th?id=ON.3E4F78E119EB7DDFC3E305E5A0A6A184
        width: 700
        height: 467
  - title: "Transgene and NEC Start Two Clinical Trials with TG4050, an AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers"
    excerpt: "capabilities - Novel immunotherapy is fully tailored to each individual by generating an immune response that targets highly specific patient tumor mutations - First patients enrolled in two Phase 1 trials at the Mayo Clinic and Toulouse Oncopole TOKYO,"
    publishedDateTime: 2020-01-07T02:06:00Z
    sourceUrl: https://www.benzinga.com/pressreleases/20/01/a15081848/transgene-and-nec-start-two-clinical-trials-with-tg4050-an-ai-powered-cancer-vaccine-for-ovarian-a
    ampUrl: https://amp.benzinga.com/amp/content/15081848
    cdnAmpUrl: https://amp-benzinga-com.cdn.ampproject.org/c/s/amp.benzinga.com/amp/content/15081848
    type: article
    provider:
      name: Benzinga.com
      domain: benzinga.com
    quality: 14
  - title: "Transgene and NEC Start Two Clinical Trials with TG4050, an Individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers"
    excerpt: "“As each patient’s cancer is unique, we have developed a therapy that turns their solid tumor’s genetic signature into ... Our partnership with NEC ensures that TG4050 is benefitting from its world-leading expertise in artificial intelligence and its unique algorithm that is used to select up to 30 patient-specific antigens that allow ..."
    publishedDateTime: 2020-01-07T07:23:00Z
    sourceUrl: https://www.sharewise.com/us/news_articles/Transgene_and_NEC_Start_Two_Clinical_Trials_with_TG4050_an_Individualized_AIPowered_Cancer_Vaccine_Transgene_BusinessWireEN_20200107_0800.html
    type: article
    provider:
      name: sharewise.com
      domain: sharewise.com
    quality: 0

secured: "8nqKD0dysOYiQwp1oUzBcQXucya5baIp5OxiSocg778vmNOq76IMHaBTntUUaBCNjbWnPL9iDfYy8shTfHGCmwGhjXJ+/tleB6UqeKI3DNc12q/MhvblEdWIJyrQ0YTkDfXpYrECTz4FnRz/q+k1jHybr3DSbmcqpJkRh99SamvOFyBDe5ehVRUNMl6uxtB9fidbV7DSimSOcNQNilhCZRo0xblEvGufoDvxo6rfN4h3SOZJG7ZvuNZwdZE0+7AFx4+cuJ1eGrxfe86CWRmT4Q==;pXS1avKASrCGqRf1aUxZAw=="
---

